COLLEGEVILLE, Pa. - eTradeWire -- Plasma-Activated Nitric Oxide Cream Outperforms L-Arginine Skincare - New Research Explains Why
Collegeville, PA - May 5, 2026 - AJPlasmaTech LLC, developer of FULGUR® Cosmetics, has published new research identifying four independent biochemical mechanisms that systematically limit the effectiveness of L-arginine-based skincare products - and demonstrates how plasma-activated nitric oxide bypasses these limitations entirely.
The L-Arginine Problem
Most nitric oxide skincare products rely on L-arginine, an amino acid that the body converts into NO through the enzyme eNOS. According to the research, this approach fails under the exact conditions where NO therapy is most needed:
eNOS uncoupling - under oxidative stress, the enzyme stops producing NO and instead generates harmful superoxide radicals. ADMA inhibition - a naturally occurring molecule blocks eNOS activity, with levels rising with age and inflammation. Arginase competition - a competing enzyme redirects L-arginine away from NO synthesis. Skin barrier limitations - L-arginine's hydrophilic molecular structure prevents effective penetration through the stratum corneum.

More on eTradeWire News

• The WestMob Heats Up Summer 2026 with the Release of New Dance Anthem 'Private Party'
• Georgia's Rainbow Village Shows Appreciation for its Volunteers Ahead of Historic Expansion
• 2026 Executive Job Search Snapshot Identifies Shifts in Hiring Timelines, Visibility, & Candidate P
• BarnOps Launches Equine Facility Management Software with GPS Staff Tracking and Weather Alerts
• Choe's HapKiDo of Jefferson, GA Supports Families Seeking Structured After-School Activities

"The patients who need nitric oxide most are precisely those for whom L-arginine works least," the research states.
The NOXAVEX Solution
FULGUR® products use a proprietary Magnetic Arc Plasma System (MAPS) to generate NO directly from atmospheric air - without chemical precursors or synthetic reagents. Through the Zeldovich mechanism, nitrogen and oxygen molecules in air are excited by high-voltage plasma discharge to produce pure nitric oxide, which is then infused directly into a lipid-based cream formulation.
This approach - which the company's scientists refer to as the NOXAVEX effect - delivers biologically active NO directly to skin tissue, bypassing eNOS entirely. Laboratory data confirms NOx concentrations of up to 250 ppm in finished formulations, with 88% activity retention after six months at 40°C.
Clinical Relevance
The eNOS-independent delivery mechanism makes plasma-stabilized NO effective in conditions where conventional approaches fail: diabetic foot ulcers, chronic wound healing, age-related skin degeneration, onychomycosis, and anti-aging applications.

More on eTradeWire News

• South Florida's Summer Business Expo Is Back! The Biz To Biz Summer Business Expo at Gulfstream Park
• Berkshire Hathaway HomeServices Florida Network Realty Honors Award-Winning Top Producers
• Maritime Association of the Port of New York & New Jersey Honors Industry Leaders at Sold-out Event
• HCC to Host Webinar on New Markets Tax Credits for Community Facilities
• Kaiya Wynn Ignites New Momentum With "Yes," a Bold New Vibe From Rising Artist to Watch

Unlike pharmaceutical NO donors such as nitroglycerin, plasma-activated formulations contain no organic nitrates and do not induce tolerance.
About AJPlasmaTech LLC
AJPlasmaTech LLC is a plasma technology company based in Collegeville, Pennsylvania, developing plasma-activated solutions for cosmetic and food preservation applications. The company holds USPTO Trademark Registration No. 8,215,955 for the FULGUR® mark. U.S. Patent Pending for its NO infusion methodology.
Full research available at: https://www.fulgurcosmetics.com/post/the-vivonox-effect-why-plasma-activated-nitric-oxide-outperforms-every-l-arginine-skincare-product
Contact:
Jennifer Blackbay, CEO
jb@ajplasmatech.com
fulgurcosmetics.com